SCHEMBL107698

SCHEMBL107698

CC(N)NC(CS)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
MAPT P10636 1/20 0.52
THRB P10828 1/20 0.52
ALOX15 P16050 1/20 0.52
NFKB1 P19838 1/20 0.52
PTGS2 P35354 1/20 0.52
THPO P40225 1/20 0.52
RECQL P46063 1/20 0.52
BLM P54132 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
ACE P12821 1/20 0.52
ENPEP Q07075 4/20 0.45
PTGS1 P23219 1/20 0.44
SLC7A11 Q9UPY5 1/20 0.44
FOLH1 Q04609 3/20 0.40
SLC7A5 Q01650 2/20 0.37
NAALAD2 Q9Y3Q0 2/20 0.36
TGFBR1 P36897 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LAP3 P28838 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1428936 1.00 KDM4E (0.52) KDM4EMAPTTHRBALOX15NFKB1
Hydrochloric Acid SCHEMBL1574245 0.98 ACE (0.50) KDM4EMAPTTHRBALOX15NFKB1
Hydrochloric Acid SCHEMBL19332925 0.98 ACE (0.50) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1058215 0.82 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL25761663 0.82 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1058214 0.82 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL28854052 0.82 KDM4E (0.56) KDM4EMAPTTHRBALOX15NFKB1
SCHEMBL1934656 0.80 TGFBR1 (0.52) FOLH1SLC7A5NAALAD2TGFBR1ALDH1A1
SCHEMBL28581576 0.80 TGFBR1 (0.52) FOLH1SLC7A5NAALAD2TGFBR1ALDH1A1
SCHEMBL23552453 0.80 KDM4E (0.54) KDM4EMAPTTHRBALOX15NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4359560-B1 MULTIRESIDUAL METHOD FOR DETECTING AND/OR QUANTIFYING AMINO ACIDS, ORGANIC ACIDS AND/OR MODIFIED NUCLEOTIDES BY MEANS OF HILIC CHROMATOGRAPHIC SEPARATION AND MS/MS CRESCENDO CARE S R L (IT) 2025-05-07 EP claimed
US-20240288409-A1 MULTIRESIDUAL METHOD FOR DETECTING AND/OR QUANTIFYING AMINO ACIDS, ORGANIC ACIDS AND/OR MODIFIED NUCLEOTIDES BY MEANS OF HILIC CHROMATOGRAPHIC SEPARATION AND MS/MS CRESCENDO CARE S.R.L. (IT) 2024-08-29 US claimed
CN-117897500-A Multi-residue method for detecting and/or quantifying amino acids, organic acids and/or modified nucleotides by affinity chromatography and MS/MS 渐进护理有限责任公司 2024-04-16 CN claimed
EP-4237427-A1 ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS University of Utah Research Foundation (US) 2023-09-06 EP claimed
CN-116670151-A Antibacterial cyclic peptides targeting acinetobacter and other gram negative pathogens 犹他大学研究基金会 2023-08-29 CN claimed
WO-2022094273-A1 ANTIBACTERIAL CYCLOPEPTIDES TARGETING ACINETOBACTER AND OTHER GRAM-NEGATIVE PATHOGENS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2022-05-05 WO claimed
US-11084836-B2 Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same THE UNIVERSITY OF TOLEDO (US) 2021-08-10 US claimed
US-20190270786-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. 2019-09-05 US claimed
WO-2018022937-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS, INC. (US) 2018-02-01 WO claimed
CN-106442758-A Liquid mass spectrometry method for detecting various amino acids in human blood plasma in underivatized mode 陈大为 2017-02-22 CN claimed
EP-1412515-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS Genset (FR) 2004-04-28 EP claimed
WO-2002066672-A2 TREATMENT OF CNS DISORDERS USING D-AMINO ACID OXIDASE AND D-ASPARTATE OXIDASE ANTAGONISTS GENSET S.A. (FR) 2002-08-29 WO claimed
US-20020046973-A1 Computerized method and apparatus for analyzing amino acids HITACHI, LTD. (JP) 2002-04-25 US claimed
US-6297054-B1 RECOMBINANT CHIMERIC DNA CONSTRUCT FOR SELECTION OF TRANSFORMED PLASTIDS; INCLUDES EDITED PLASTID GENE FUSED TO CODING REGION OF SELECTABLE MARKER RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2001-10-02 US claimed
US-6018103-A A CHIMERIC GENE COMPRISING OF SMALL NUCLEAR RNA OR MESSENGER RNA PROMOTER SPECIFIC FOR RNA POLYMERASE II AND SMALL NUCLEAR RNA TERMINATION ELEMENT FROM PLANTS; BOTH ELEMENTS FUNCTION INDEPENDENT OF THE OTHER; EXPRESSING CHIMERIC GENES IN PLANTS NOVARTIS FINANCE CORPORATION (US) 2000-01-25 US claimed
EP-0703987-A1 CHIMERIC PLANT GENES POSSESSING INDEPENDENT REGULATORY SEQUENCES Novartis AG (CH) 1996-04-03 EP claimed
WO-1995000652-A1 CHIMERIC PLANT GENES POSSESSING INDEPENDENT REGULATORY SEQUENCES CIBA-GEIGY AG (CH) 1995-01-05 WO claimed
US-5316930-A DNA molecules and plant or bacteria cells PIONEER HI-BRED INTERNATIONAL, INC. (US) 1994-05-31 US claimed
EP-0240332-A2 Virus resistant plants having antisense RNA PIONEER HI-BRED INTERNATIONAL, INC. (US) 1987-10-07 EP claimed
EP-0240331-A2 Virus resistant plants having a viral coat protein PIONEER HI-BRED INTERNATIONAL, INC. (US) 1987-10-07 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270786-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 AND THEIR USE TO TREAT INFLAMMATORY DISEASES IL23R, IL17A, VIP KDM4E 4540/4885MAPT 1474/4885THRB 3200/4885
US-11084836-B2 Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same TFEB, SQSTM1, BECN1 KDM4E 235/4885MAPT 215/4885THRB 2653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.